Skip to main content
SpringerLink
Log in

Aggressive non-Hodgkin’s lymphoma: improved prognosis with combination chemotherapy

  • New Drugs and Disease Management
  • Published:
Drugs & Therapy Perspectives Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Martelli M, De Sanctis V, Avvisati G, et al. Current guidelines for the management of aggressive non-Hodgkin’s lymphoma. Drugs 1997 Jun; 53(6): 957–72

    Article  PubMed  CAS  Google Scholar 

  2. Weisenburger DD. Epidemiology of non-Hodgkin’s lymphoma: recent findings regarding an emerging epidemic. Ann Oncol 1994; 5(9): 19–24

    PubMed  Google Scholar 

  3. Shipp MA, Harrington DP, Anderson JR, et al. A predictive model for aggressive NHL: the international non-Hodgkins lymphoma factors project. N Engl J Med 1993; 329: 987–94

    Article  Google Scholar 

  4. Gordon LI, Harringhton D, Andersen PDJ, et al. Comparison of a second-generation combination chemotherapy regimen (m-BACOD) with a standard regimen (CHOP) for advanced diffuse non-Hodgkins NHL. N Engl J Med 1992; 327: 1342–9

    Article  PubMed  CAS  Google Scholar 

  5. Montserrat E, Garcia-Conde J, Vinolas N, et al. ProMACE-CytaBOM vs CHOP in the treatment of unfavorable lymphomas: a randomized trial [abstract]. Blood 1991; 78: 127A

    Google Scholar 

  6. Cooper IA, Wolf MM, Robertson TI, et al. Randomized comparison of MACOP-B with CHOP in patients with intermediate-grade non-Hodgkin’s lymphoma. J Clin Oncol 1994; 12: 769–78

    PubMed  CAS  Google Scholar 

  7. Fisher RI. CHOP is the current standard for the treatment of high risk patients with diffuse large cell lymphoma [abstract no. 036]. VIth International Conference on Malignant Lymphoma; 1996 Jun 5–8: Lugano. Ann Oncol 1996; 7 Suppl. 3: 12

    Google Scholar 

  8. Bertini M, Orsucci L, Vitolo U, et al. Stage II large B-cell lymphoma with sclerosis treated with MACOP-B. Ann Oncol 1991; 2: 733–7

    PubMed  CAS  Google Scholar 

  9. Lazzarino M, Orlandi E, Paulli M, et al. Primary mediastinal B-cell lymphoma with sclerosis: an aggressive tumor with distinctive clinical and pathologic features. J Clin Oncol 1993; 11(12): 2306–13

    PubMed  CAS  Google Scholar 

  10. Falini B, Venturi S, Martelli M, et al. Mediastinal large B-cell lymphoma: clinical and immunohistological findings in 18 patients treated with different third-generation regimens. Br J Haematol 1995; 89: 780–9

    Article  PubMed  CAS  Google Scholar 

  11. Haioun C, Gaulard P, Roudot-Thovaral F, et al. Mediastinal diffuse large-cell lymphoma with sclerosis: a condition with a poor prognosis. Am J Clin Oncol 1989; 12: 425–9

    Article  PubMed  CAS  Google Scholar 

  12. Todeschini G, Ambrosetti A, Meneghini V, et al. Mediastinal large B-cell lymphoma with sclerosis: a clinical study of 21 patients. J Clin Oncol 1990; 8: 804–8

    PubMed  CAS  Google Scholar 

  13. Lavabre-Bertrand T, Donadio D, Feguex N, et al. A study of 15 cases of primary mediastinal lymphoma of B-cell type. Cancer 1992; 69: 2561–6

    Article  PubMed  CAS  Google Scholar 

  14. Longo DL, Glatstein E, Duffey PL, et al. Treatment of localized aggressive lymphomas with combination chemotherapy followed by involved-field radiation therapy. J Clin Oncol 1989; 9: 1295–302

    Google Scholar 

  15. Tondini C, Zanini M, Lombardi F, et al. Combined modality treatment with primary CHOP chemotherapy followed by locoregional irradiation in stage I or II histologically aggressive non-Hodgkin’s lymphomas. J Clin Oncol 1993; 4: 720–5

    Google Scholar 

  16. Connors JM, Klimo P, Fairey RN, et al. Brief chemotherapy and involved field radiation therapy for limited-stage, histologically aggressive lymphoma. Ann Intern Med 1987; 107: 25–30

    PubMed  CAS  Google Scholar 

  17. Miller TP, Dahlberg S, Cassady JR, et al. Three cycles of CHOP (3) plus radiotherapy (RT) is superior to eight cycles of CHOP (8) alone for localized intermediate and high grade non-Hodgkins lymphoma: a Southwest Oncology Study Group [abstract no. 1257]. Proceedings of the XXXIIth ASCO Meeting; 1996 May 18–21: Philadelphia

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Aggressive non-Hodgkin’s lymphoma: improved prognosis with combination chemotherapy. Drugs Ther. Perspect 11, 5–8 (1998). https://doi.org/10.2165/00042310-199811060-00002

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00042310-199811060-00002

Keywords

Search

Navigation